{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T10:54:13Z","timestamp":1784199253233,"version":"3.55.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82300384"],"award-info":[{"award-number":["82300384"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370267"],"award-info":[{"award-number":["82370267"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81870204"],"award-info":[{"award-number":["81870204"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFA1205000"],"award-info":[{"award-number":["2022YFA1205000"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2024ZD0531701"],"award-info":[{"award-number":["2024ZD0531701"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Jiangsu Province Natural Science Foundation","doi-asserted-by":"publisher","award":["BK20220175"],"award-info":[{"award-number":["BK20220175"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2023M731625"],"award-info":[{"award-number":["2023M731625"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.bcp.2026.117877","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T16:40:37Z","timestamp":1773074437000},"page":"117877","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Finerenone improves doxorubicin-induced cardiotoxicity by inhibiting cardiomyocyte apoptosis through the TAK1-p38 axis"],"prefix":"10.1016","volume":"249","author":[{"given":"Xingyi","family":"Lai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huihui","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaojun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2026.117877_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2023.101205","article-title":"Doxorubicin and other anthracyclines in cancers: activity, chemoresistance and its overcoming","volume":"93","author":"Mattioli","year":"2023","journal-title":"Mol. Aspects Med."},{"issue":"2","key":"10.1016\/j.bcp.2026.117877_b0010","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/1097-0142(197308)32:2<302::AID-CNCR2820320205>3.0.CO;2-2","article-title":"A clinicopathologic analysis of adriamycin cardiotoxicity","volume":"32","author":"Lefrak","year":"1973","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.bcp.2026.117877_b0015","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/cncr.11407","article-title":"Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials","volume":"97","author":"Swain","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.bcp.2026.117877_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113903","article-title":"Research progress of therapeutic drugs for doxorubicin-induced cardiomyopathy","volume":"156","author":"Chen","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bcp.2026.117877_b0025","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202310227","article-title":"Protosappanin a protects DOX\u2010induced myocardial injury and cardiac dysfunction by targeting ACSL4\/FTH1 axis\u2010dependent ferroptosis","author":"Cui","year":"2024","journal-title":"Adv. Sci."},{"key":"10.1016\/j.bcp.2026.117877_b0030","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.phrs.2017.03.016","article-title":"Doxorubicin targets multiple players: a new view of an old problem","volume":"127","author":"Cappetta","year":"2018","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.bcp.2026.117877_b0035","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.tips.2022.10.003","article-title":"Mitochondrial quality control mechanisms as therapeutic targets in doxorubicin-induced cardiotoxicity","volume":"44","author":"Wu","year":"2023","journal-title":"Trends Pharmacol. Sci."},{"issue":"7838","key":"10.1016\/j.bcp.2026.117877_b0040","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/s41586-020-2797-4","article-title":"Cells of the adult human heart","volume":"588","author":"Litvi\u0148ukov\u00e1","year":"2020","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bcp.2026.117877_b0045","article-title":"Cardiomyocyte-specific knockout of ADAM17 alleviates doxorubicin-induced cardiomyopathy via inhibiting TNF\u03b1\u2013TRAF3\u2013TAK1\u2013MAPK axis","volume":"9","author":"Xie","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bcp.2026.117877_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107281","article-title":"Programmed death of cardiomyocytes in cardiovascular disease and new therapeutic approaches","volume":"206","author":"Cai","year":"2024","journal-title":"Pharmacol. Res."},{"issue":"5","key":"10.1016\/j.bcp.2026.117877_b0055","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/s41419-022-04923-5","article-title":"Programmed cell death in atherosclerosis and vascular calcification","volume":"13","author":"Li","year":"2022","journal-title":"Cell Death Dis."},{"issue":"13","key":"10.1016\/j.bcp.2026.117877_b0060","doi-asserted-by":"crossref","first-page":"9166","DOI":"10.1021\/acs.jmedchem.1c00384","article-title":"Discovery of \u03b2-carboline derivatives as a highly potent cardioprotectant against myocardial ischemia-reperfusion injury","volume":"64","author":"Zhang","year":"2021","journal-title":"J. Med. Chem."},{"issue":"15","key":"10.1016\/j.bcp.2026.117877_b0065","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1007\/s40265-021-01599-7","article-title":"Finerenone: first approval","volume":"81","author":"Frampton","year":"2021","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.bcp.2026.117877_b0070","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur. Heart J."},{"issue":"1","key":"10.1016\/j.bcp.2026.117877_b0075","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41581-021-00490-8","article-title":"Mineralocorticoid receptor antagonists in diabetic kidney disease - mechanistic and therapeutic effects","volume":"18","author":"Barrera-Chimal","year":"2022","journal-title":"Nat. Rev. Nephrol."},{"issue":"3","key":"10.1016\/j.bcp.2026.117877_b0080","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24032536","article-title":"Benefits of the non-steroidal mineralocorticoid receptor antagonist finerenone in metabolic syndrome-related heart failure with preserved ejection fraction","volume":"24","author":"Lima-Posada","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.bcp.2026.117877_b0085","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1161\/HYPERTENSIONAHA.117.10360","article-title":"Selective mineralocorticoid receptor cofactor modulation as molecular basis for finerenone\u2019s antifibrotic activity","volume":"71","author":"Grune","year":"2018","journal-title":"Hypertension"},{"issue":"6","key":"10.1016\/j.bcp.2026.117877_b0090","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1161\/CIRCULATIONAHA.121.057983","article-title":"Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD trial","volume":"145","author":"Filippatos","year":"2022","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.bcp.2026.117877_b0095","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1681\/ASN.2021070942","article-title":"Hyperkalemia risk with finerenone: results from the FIDELIO-DKD trial","volume":"33","author":"Agarwal","year":"2022","journal-title":"J Am. Soc. Nephrol."},{"issue":"6","key":"10.1016\/j.bcp.2026.117877_b0100","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur. Heart J."},{"issue":"2","key":"10.1016\/j.bcp.2026.117877_b0105","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/s00125-023-06031-1","article-title":"Mineralocorticoid receptor overactivation: targeting systemic impact with non-steroidal mineralocorticoid receptor antagonists","volume":"67","author":"Savarese","year":"2024","journal-title":"Diabetologia"},{"key":"10.1016\/j.bcp.2026.117877_b0110","article-title":"Non-steroidal mineralocorticoid receptor antagonist finerenone ameliorates mitochondrial dysfunction via PI3K\/Akt\/eNOS signaling pathway in diabetic tubulopathy","volume":"68","author":"Wang","year":"2023","journal-title":"Redox Biol."},{"issue":"1","key":"10.1016\/j.bcp.2026.117877_b0115","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s13098-023-01064-3","article-title":"Finerenone attenuates myocardial apoptosis, metabolic disturbance and myocardial fibrosis in type 2 diabetes mellitus","volume":"15","author":"Jin","year":"2023","journal-title":"Diabetol. Metab. Syndr."},{"issue":"5","key":"10.1016\/j.bcp.2026.117877_b0120","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.14336\/AD.2023.0219","article-title":"TAK1 improves cognitive function via suppressing RIPK1-driven neuronal apoptosis and necroptosis in rats with chronic hypertension","volume":"14","author":"Yang","year":"2023","journal-title":"Aging Dis."},{"issue":"5","key":"10.1016\/j.bcp.2026.117877_b0125","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1007\/s12265-024-10525-7","article-title":"Vaccarin ameliorates doxorubicin-induced cardiotoxicity via inhibition of p38 MAPK mediated mitochondrial dysfunction","volume":"17","author":"Shi","year":"2024","journal-title":"J. Cardiovasc. Transl. Res."},{"key":"10.1016\/j.bcp.2026.117877_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2020.101445","article-title":"A stress response p38 MAP kinase inhibitor SB202190 promoted TFEB\/TFE3-dependent autophagy and lysosomal biogenesis independent of p38","volume":"32","author":"Yang","year":"2020","journal-title":"Redox Biol."},{"issue":"39","key":"10.1016\/j.bcp.2026.117877_b0135","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2308079120","article-title":"Small molecule activators of TAK1 promotes its activity-dependent ubiquitination and TRAIL-mediated tumor cell death","volume":"120","author":"Sun","year":"2023","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.bcp.2026.117877_b0140","doi-asserted-by":"crossref","DOI":"10.3390\/cells9010047","article-title":"Specific upregulation of TRPC1 and TRPC5 channels by mineralocorticoid pathway in adult rat ventricular cardiomyocytes","volume":"9","author":"Bartoli","year":"2019","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.bcp.2026.117877_b0145","first-page":"199","article-title":"N-acetylcysteine alleviates H2O2-induced damage via regulating the redox status of intracellular antioxidants in H9c2 cells","volume":"43","author":"Liu","year":"2019","journal-title":"Int. J. Mol. Med."},{"issue":"11","key":"10.1016\/j.bcp.2026.117877_b0150","doi-asserted-by":"crossref","first-page":"e223","DOI":"10.1161\/CIRCRESAHA.122.321587","article-title":"Critical role of the cGAS-STING pathway in doxorubicin-induced cardiotoxicity","volume":"132","author":"Luo","year":"2023","journal-title":"Circ. Res."},{"key":"10.1016\/j.bcp.2026.117877_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2023.103024","article-title":"Pharmacological activation of GPX4 ameliorates doxorubicin-induced cardiomyopathy","volume":"70","author":"Huang","year":"2024","journal-title":"Redox Biol."},{"key":"10.1016\/j.bcp.2026.117877_b0160","article-title":"Dexrazoxane for the treatment of chemotherapy-related side effects","volume":"6","author":"Langer","year":"2014","journal-title":"Cancer Manag. Res."},{"issue":"10106","key":"10.1016\/j.bcp.2026.117877_b0165","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1016\/S0140-6736(17)31071-1","article-title":"Heart failure","volume":"390","author":"Metra","year":"2017","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.bcp.2026.117877_b0170","article-title":"The novel mineralocorticoid receptor antagonist finerenone attenuates neointima formation after vascular injury","volume":"12","author":"Alvarez de la Rosa","year":"2017","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.bcp.2026.117877_b0175","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/cvr\/cvaf022","article-title":"Thousand and one amino acid protein kinase 1 suppression improves doxorubicin-induced cardiomyopathy by preventing cardiomyocyte death and dysfunction","volume":"121","author":"Suga","year":"2025","journal-title":"Cardiovasc. Res."},{"issue":"21","key":"10.1016\/j.bcp.2026.117877_b0180","doi-asserted-by":"crossref","first-page":"4857","DOI":"10.1016\/j.biomaterials.2011.03.048","article-title":"The protective role of arjunolic acid against doxorubicin induced intracellular ROS dependent JNK-p38 and p53-mediated cardiac apoptosis","volume":"32","author":"Ghosh","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.bcp.2026.117877_b0185","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.cbi.2019.03.027","article-title":"Chitosan oligosaccharides prevent doxorubicin-induced oxidative stress and cardiac apoptosis through activating p38 and JNK MAPK mediated Nrf2\/ARE pathway","volume":"305","author":"Zhang","year":"2019","journal-title":"Chem. Biol. Interact."},{"issue":"5","key":"10.1016\/j.bcp.2026.117877_b0190","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1093\/nar\/gkad057","article-title":"Lin, p38-mediated FOXN3 phosphorylation modulates lung inflammation and injury through the NF-\u03baB signaling pathway","volume":"51","author":"Zhu","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bcp.2026.117877_b0195","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ejphar.2017.12.021","article-title":"A novel compound DT-010 protects against doxorubicin-induced cardiotoxicity in zebrafish and H9c2 cells by inhibiting reactive oxygen species-mediated apoptotic and autophagic pathways","volume":"820","author":"Tang","year":"2018","journal-title":"Eur. J. Pharmacol."},{"issue":"7","key":"10.1016\/j.bcp.2026.117877_b0200","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1038\/s41401-023-01057-y","article-title":"Notoginsenoside R1 protects against myocardial ischemia\/reperfusion injury in mice via suppressing TAK1-JNK\/p38 signaling","volume":"44","author":"Zeng","year":"2023","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.bcp.2026.117877_b0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.116009","article-title":"Upregulation of TRIM16 mitigates doxorubicin-induced cardiotoxicity by modulating TAK1 and YAP\/Nrf2 pathways in mice","volume":"220","author":"Guo","year":"2024","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2026.117877_b0210","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.yjmcc.2016.12.004","article-title":"NADPH oxidase 4 regulates vascular inflammation in aging and atherosclerosis","volume":"102","author":"Lozhkin","year":"2017","journal-title":"J. Mol. Cell. Cardiol."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226002091?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226002091?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T22:15:26Z","timestamp":1778710526000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295226002091"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":42,"alternative-id":["S0006295226002091"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.117877","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Finerenone improves doxorubicin-induced cardiotoxicity by inhibiting cardiomyocyte apoptosis through the TAK1-p38 axis","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.117877","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"117877"}}